MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

AveXis Company Profile (NASDAQ:AVXS)

Consensus Ratings for AveXis (NASDAQ:AVXS) (?)
Ratings Breakdown: 1 Hold Rating(s), 3 Buy Rating(s)
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $45.00 (16.97% upside)

Analysts' Ratings History for AveXis (NASDAQ:AVXS)
Show:
DateFirmActionRatingPrice TargetActions
6/22/2016Jefferies GroupDowngradeBuy -> Hold$39.00 -> $42.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/13/2016Goldman SachsBoost Price TargetBuy$28.00 -> $47.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/9/2016Chardan CapitalReiterated RatingBuy$60.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/7/2016BMO Capital MarketsInitiated CoverageOutperform$31.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/26/2014 forward)
Earnings History for AveXis (NASDAQ:AVXS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
5/12/2016        
5/12/2016Q1($0.35)($1.24)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for AveXis (NASDAQ:AVXS)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for AveXis (NASDAQ:AVXS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for AveXis (NASDAQ:AVXS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
2/17/2016Bong Y KohDirectorBuy100,000$20.00$2,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/17/2016James E FlynnInsiderBuy750,317$19.47$14,608,671.99View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for AveXis (NASDAQ:AVXS)
DateHeadline
06/24/16 04:16 PMAVEXIS, INC. Files SEC form 8-K, Change in Directors or Principal Officers -
06/23/16 10:28 AMAveXis (NASDAQ:AVXS) price target bumped up to $42 as announced today by Jefferies & Co
06/22/16 02:39 PMJefferies Downgrades AveXis, Cites Valuation
06/10/16 08:33 AMThese 5 Stocks Are Poised for Breakouts -
06/06/16 04:18 PMAveXis to Present at Goldman Sachs Annual Global Healthcare Conference and Jefferies 2016 Healthcare Conference - [at noodls] - CHICAGO, June 06, 2016 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing novel treatments for patients suffering from rare and life-threatening neurological ...
06/02/16 10:04 AMAveXis (AVXS) is in Overbought Territory: What's Next? -
06/02/16 07:40 AMAveXis (AVXS) Looks Good: Stock Adds 6.5% in Session -
05/23/16 07:06 AMManufacturing Stocks Daily Roundup - Contrafect Common (CFRX)- The company’s stocks surged 11.87 pct. Avexis Inc Cmn Stk (AVXS)- AVXS stock is up 11.33 pct. Genocea Biosciences (GNCA)- The company’s stocks surged 11.39 pct. Flex Pharma Inc. Cm (FLKS)- The company’s shares rose 11.08 pct.
05/16/16 07:32 AMAveXis Presents Pulmonary Data from Ongoing Phase 1 Trial of AVXS-101 in Spinal Muscular Atrophy Type 1 - [at noodls] - CHICAGO, May 16, 2016 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing novel treatments for patients suffering from rare and life-threatening neurological ...
05/13/16 03:29 PMAVEXIS, INC. Files SEC form 10-Q, Quarterly Report -
05/13/16 08:25 AMEdited Transcript of AVXS earnings conference call or presentation 12-May-16 8:30pm GMT -
05/12/16 04:04 PMAveXis (AVXS) Shares March Higher, Can It Continue? - As of late, it has definitely been a great time to be an investor in AveXis, Inc. AVXS. The stock has moved higher by 55.2% in the past month, while it is also above its 20 Day SMA too. This combination of strong price performance and favorable technical ...
05/12/16 03:01 PMAveXis Reports First Quarter 2016 Financial and Operating Results - [GlobeNewswire] - Encouraging interim data for lead clinical program, AVXS-101, for Spinal Muscular Atrophy Type 1. Conference call May 12 at 4:30 p.m. EDT. CHICAGO, May 12, 2016-- AveXis, Inc., a clinical-stage gene therapy ...
05/12/16 06:44 AMAveXis Inc Earnings Call (Q1 2016) - AveXis, Inc., a clinical-stage gene therapy company, engages in developing and commercializing novel treatments for patients suffering from rare and life-threatening neurological genetic diseases. Its initial product candidate is AVXS-101, a gene therapy ...
05/12/16 06:07 AMQ1 2016 AveXis Inc Earnings Release - After Market Close -
05/11/16 09:03 AMDrug Stocks' Earnings Slated for This Week: RDY, AVXS, ESALY -
05/11/16 09:03 AMDrug Stocks' Earnings Slated for This Week: RDY, AVXS, ESALY -
05/10/16 07:08 AMAveXis (AVXS), Argos (ARGS), Depomed (DEPO) Top Moving Stocks at the Close - AveXis Inc (AVXS) traded at $31.41 + 6.08 (24.00 percent) on 236,111 stock volume. The company is — year to date, and — during the past four quarters. Argos Therapeutics Inc. (ARGS) traded at $6.91 + 1.06 (18.12 percent) on 1,197,403 stock volume.
05/06/16 04:18 PMREMINDER/Media Advisory: Correctional Service of Canada Invites Media to Tour Collins Bay Institution - 28p AVEXIS: Reports Data from Ongoing Phase 1 Trial of AVXS-101 in Spinal Muscular Atrophy Type 1 09:27p ICAD INC: Submission of Matters to a Vote of Security Holders (form 8-K) 09:27p COMMSCOPE HOLDING COMPANY, INC.: Submission of Matters to a Vote of ...
05/06/16 04:18 PMAveXis (AVXS) Announces Phase 1 Trial Data for AVXS-101 in SMA Type 1 - AveXis, Inc. (NASDAQ: AVXS), a clinical-stage gene therapy company developing novel treatments for patients suffering from rare and life-threatening neurological genetic diseases, today presented an interim analysis of data as of April 1, 2016 from the ...
05/06/16 02:34 PMAveXis Reports Data from Ongoing Phase 1 Trial of AVXS-101 in Spinal Muscular Atrophy Type 1 - [at noodls] - -- Jerry Mendell, MD, Presented Data as of April 1, 2016 at the American Society of Gene & Cell Therapy 19 Annual Meeting -- -- Company to Host Webcast Today at 4:30 p.m. Eastern Daylight Time -- CHICAGO, ...
05/06/16 02:11 PMAVEXIS, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits -
05/06/16 02:11 PM3:11 pm AveXis presents an interim analysis of data as of April 1 from the ongoing Phase 1 trial of AVXS-101 for the treatment of spinal muscular atrophy Type 1 -
05/05/16 11:40 PMOverseas Shipholding Group Inc Earnings Call scheduled for 4:30 pm ET today -
05/05/16 07:21 AMAveXis to Report First Quarter 2016 Financial Results on Thursday, May 12 - [at noodls] - CHICAGO, May 05, 2016 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic ...
04/26/16 06:49 AMAZN Breathes Easy, EXEL Scores FDA Nod, SRPT Disappointed, PETX On The Rise - AZN closed Monday's trading at $30.01, down 0.30%. In after hours, the stock was up 1.63% to $30.50. On May 6, 2016, AveXis Inc. ( AVXS) will present data as of April 1, 2016 from the ongoing phase 1 clinical trial of AVXS-101 in Spinal Muscular Atrophy ...
04/25/16 09:14 AMAveXis to Report Data from Ongoing Phase 1 Clinical Trial of AVXS-101 in Spinal Muscular Atrophy Type 1 - [at noodls] - -- Jerry Mendell, M.D., to Present Data as of April 1, 2016 at the American Society of Gene & Cell Therapy 19th Annual Meeting -- -- Company to Host Webcast on Friday, May 6, 2016 at 4:30 p.m. Eastern ...
03/24/16 12:04 PMAVEXIS, INC. Financials -
03/18/16 04:05 PMAVEXIS, INC. Files SEC form 10-K, Annual Report -
03/17/16 05:35 AMEarnings Reported After The Bell Mar.16 - AveXis, Inc. (AVXS) Q4 net loss was $13.2 million compared to net loss of $3.7 million a year ago. Jabil Circuit Inc. (JBL) Q2 profit rose to $78.9 million or $0.41 per share from $52.0 million or $0.27 per share last year. Core earnings for the quarter ...
03/17/16 02:13 AMEdited Transcript of AVXS earnings conference call or presentation 16-Mar-16 8:30pm GMT -
03/16/16 03:30 PMAVEXIS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits -
03/16/16 03:30 PMAveXis Inc Earnings Call scheduled for 4:30 pm ET today -
03/16/16 03:01 PMAveXis Reports Fourth Quarter and Full Year 2015 Financial and Operating Results - [GlobeNewswire] - --Initial public offering raised $98.2 million in net proceeds--. --Encouraging interim data for lead clinical program, AVXS-101, for Spinal Muscular Atrophy Type 1–. --Conference call March 16 at 4:30 ...
03/16/16 06:07 AMQ4 2015 AveXis, Inc. Earnings Release - After Market Close -
03/16/16 05:36 AMAveXis Inc Earnings Call (Q4 2015) - AveXis, Inc., a clinical-stage gene therapy company, engages in developing and commercializing novel treatments for patients suffering from rare and life-threatening neurological genetic diseases. Its initial product candidate is AVXS-101, a gene therapy ...
03/08/16 07:00 AMAveXis to Report Full Year and Fourth Quarter 2015 Financial Results on Wednesday, March 16 - [GlobeNewswire] - CHICAGO, March 08, 2016-- AveXis, Inc., a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, will announce financial ...
03/07/16 07:00 AMAveXis Announces Appointments of Daniel G. Welch, Terrence C. Kearney and Frank Verwiel, M.D. to Board of Directors - [GlobeNewswire] - CHICAGO, March 07, 2016-- AveXis, Inc., a leading clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today announced ...
03/07/16 05:23 AMCoverage initiated on AveXis by Jefferies and Goldman -
03/02/16 04:20 AMDespite rocky market, Rockville's Regenxbio on serious growth path -
02/18/16 08:29 AMOpening Bell, February 18, 2016 -
02/18/16 08:16 AMToday's Bell Ringer, February 18, 2016 -
02/17/16 03:16 PMAVEXIS, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statement -
02/17/16 09:00 AMAveXis, Inc. (Nasdaq:AVXS) to Ring The Nasdaq Stock Market Opening Bell - [GlobeNewswire] - What: AveXis, Inc., a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, will visit the Nasdaq MarketSite in ...
02/14/16 08:27 AMBusted IPOs Underscore Lack of Appetite for Risk - [at 24/7 Wall St.] - Last week began with up to 8 initial public offerings (IPOs) on the calendar, and ended with 2 new publicly traded companies, both of which were busted IPOs. Of the other six, two have officially withdrawn ...
02/11/16 11:10 AM2 Biotechs Get Burned in IPOs - [24/7 Wall St.] - AveXis and Proteostasis Therapeutics priced their IPOs on Wednesday and shares began trading Thursday morning.
02/10/16 08:33 PMAveXis Announces Pricing of Initial Public Offering - [GlobeNewswire] - CHICAGO, Feb. 10, 2016-- AveXis, Inc., a clinical stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today announced the ...
About AveXis

AveXis logoAveXis, Inc., formerly Biolife Cell Bank, Inc., is a clinical-stage gene therapy company. The Company operates through developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company's product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration. The survival motor neuron (SMN) is a protein for normal motor neuron signaling and function. Patients with SMA Type 1 either carry a mutation in their SMN1 gene or their SMN1 genes have been deleted. AVXS-101 is designed to deliver a functional human SMN gene into the nuclei of motor neurons that then generates an increase in SMN protein levels. It also focuses to develop AVXS-101 to treat additional SMA types and other treatments for rare neurological genetic diseases.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: AVXS
  • CUSIP:
Key Metrics:
  • Previous Close: $40.32
  • 50 Day Moving Average: $40.12
  • 200 Day Moving Average: $29.37
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $885.31M
  • Current Quarter EPS Consensus Estimate: $-4.00 EPS
Additional Links:
AveXis (NASDAQ:AVXS) Chart for Sunday, June, 26, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha